65 related articles for article (PubMed ID: 7805048)
1. Treatment of experimental glioblastoma with a human major histocompatibility complex nonrestricted cytotoxic T cell line.
Cesano A; Visonneau S; Santoli D
Cancer Res; 1995 Jan; 55(1):96-101. PubMed ID: 7805048
[TBL] [Abstract][Full Text] [Related]
2. Antitumor efficacy of a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in immunocompetent mice bearing syngeneic leukemia.
Cesano A; Visonneau S; Pasquini S; Rovera G; Santoli D
Cancer Res; 1996 Oct; 56(19):4444-52. PubMed ID: 8813139
[TBL] [Abstract][Full Text] [Related]
3. TALL-104 cell therapy of human solid tumors implanted in immunodeficient (SCID) mice.
Cesano A; Visonneau S; Santoli D
Anticancer Res; 1998; 18(4A):2289-95. PubMed ID: 9703868
[TBL] [Abstract][Full Text] [Related]
4. The human leukemic T-cell line, TALL-104, is cytotoxic to human malignant brain tumors and traffics through brain tissue: implications for local adoptive immunotherapy.
Kruse CA; Visonneau S; Kleinschmidt-DeMasters BK; Gup CJ; Gomez GG; Paul DB; Santoli D
Cancer Res; 2000 Oct; 60(20):5731-9. PubMed ID: 11059767
[TBL] [Abstract][Full Text] [Related]
5. Cell therapy of a highly invasive human breast carcinoma implanted in immunodeficient (SCID) mice.
Visonneau S; Cesano A; Torosian MH; Santoli D
Clin Cancer Res; 1997 Sep; 3(9):1491-500. PubMed ID: 9815835
[TBL] [Abstract][Full Text] [Related]
6. Phase I clinical trial with a human major histocompatibility complex nonrestricted cytotoxic T-cell line (TALL-104) in dogs with advanced tumors.
Cesano A; Visonneau S; Jeglum KA; Owen J; Wilkinson K; Carner K; Reese L; Santoli D
Cancer Res; 1996 Jul; 56(13):3021-9. PubMed ID: 8674057
[TBL] [Abstract][Full Text] [Related]
7. Differential effect of high doses versus low doses of interleukin-12 on the adoptive transfer of human specific cytotoxic T lymphocyte in autologous lung tumors engrafted into severe combined immunodeficiency disease-nonobese diabetic mice: relation with interleukin-10 induction.
Asselin-Paturel C; Megherat S; Vergnon I; Echchakir H; Dorothée G; Blesson S; Gay F; Mami-Chouaib F; Chouaib S
Cancer; 2001 Jan; 91(1):113-22. PubMed ID: 11148567
[TBL] [Abstract][Full Text] [Related]
8. Successful treatment of canine malignant histiocytosis with the human major histocompatibility complex nonrestricted cytotoxic T-cell line TALL-104.
Visonneau S; Cesano A; Tran T; Jeglum KA; Santoli D
Clin Cancer Res; 1997 Oct; 3(10):1789-97. PubMed ID: 9815565
[TBL] [Abstract][Full Text] [Related]
9. Antileukemia activity of a natural killer cell line against human leukemias.
Yan Y; Steinherz P; Klingemann HG; Dennig D; Childs BH; McGuirk J; O'Reilly RJ
Clin Cancer Res; 1998 Nov; 4(11):2859-68. PubMed ID: 9829753
[TBL] [Abstract][Full Text] [Related]
10. Specific recognition and killing of glioblastoma multiforme by interleukin 13-zetakine redirected cytolytic T cells.
Kahlon KS; Brown C; Cooper LJ; Raubitschek A; Forman SJ; Jensen MC
Cancer Res; 2004 Dec; 64(24):9160-6. PubMed ID: 15604287
[TBL] [Abstract][Full Text] [Related]
11. Phase I trial of TALL-104 cells in patients with refractory metastatic breast cancer.
Visonneau S; Cesano A; Porter DL; Luger SL; Schuchter L; Kamoun M; Torosian MH; Duffy K; Sickles C; Stadtmauer EA; Santoli D
Clin Cancer Res; 2000 May; 6(5):1744-54. PubMed ID: 10815893
[TBL] [Abstract][Full Text] [Related]
12. Synergistic enhancement of antitumor immunity with adoptively transferred tumor-specific CD4+ and CD8+ T cells and intratumoral lymphotactin transgene expression.
Huang H; Li F; Gordon JR; Xiang J
Cancer Res; 2002 Apr; 62(7):2043-51. PubMed ID: 11929823
[TBL] [Abstract][Full Text] [Related]
13. Adoptive transfer of an anti-MART-1(27-35)-specific CD8+ T cell clone leads to immunoselection of human melanoma antigen-loss variants in SCID mice.
Lozupone F; Rivoltini L; Luciani F; Venditti M; Lugini L; Cova A; Squarcina P; Parmiani G; Belardelli F; Fais S
Eur J Immunol; 2003 Feb; 33(2):556-66. PubMed ID: 12645955
[TBL] [Abstract][Full Text] [Related]
14. Synergistic effects of adriamycin and TALL-104 cell therapy against a human gastric carcinoma in vivo.
Cesano A; Visonneau S; Rovera G; Santoli D
Anticancer Res; 1997; 17(3C):1887-92. PubMed ID: 9216640
[TBL] [Abstract][Full Text] [Related]
15. Rapid generation of potent and tumor-specific cytotoxic T lymphocytes by interleukin 18 using dendritic cells and natural killer cells.
Tanaka F; Hashimoto W; Okamura H; Robbins PD; Lotze MT; Tahara H
Cancer Res; 2000 Sep; 60(17):4838-44. PubMed ID: 10987295
[TBL] [Abstract][Full Text] [Related]
16. Human tumor antigen-specific T lymphocytes and interleukin-2-activated natural killer cells: comparisons of antitumor effects in vitro and in vivo.
Whiteside TL; Sung MW; Nagashima S; Chikamatsu K; Okada K; Vujanovic NL
Clin Cancer Res; 1998 May; 4(5):1135-45. PubMed ID: 9607570
[TBL] [Abstract][Full Text] [Related]
17. Antitumor immune response of human peripheral blood lymphocytes coengrafted with tumor into severe combined immunodeficient mice.
Iwanuma Y; Chen FA; Egilmez NK; Takita H; Bankert RB
Cancer Res; 1997 Jul; 57(14):2937-42. PubMed ID: 9230205
[TBL] [Abstract][Full Text] [Related]
18. Human cytotoxic T-cells suppress the growth of spontaneous melanoma metastases in SCID/hu mice.
Sabzevari H; Reisfeld RA
Cancer Res; 1993 Oct; 53(20):4933-7. PubMed ID: 8402683
[TBL] [Abstract][Full Text] [Related]
19. Use of a lethally irradiated major histocompatibility complex nonrestricted cytotoxic T-cell line for effective purging of marrows containing lysis-sensitive or -resistant leukemic targets.
Cesano A; Pierson G; Visonneau S; Migliaccio AR; Santoli D
Blood; 1996 Jan; 87(1):393-403. PubMed ID: 8547668
[TBL] [Abstract][Full Text] [Related]
20. Induction of immunity in peripheral tissues combined with intracerebral transplantation of interleukin-2-producing cells eliminates established brain tumors.
Iwadate Y; Yamaura A; Sato Y; Sakiyama S; Tagawa M
Cancer Res; 2001 Dec; 61(24):8769-74. PubMed ID: 11751397
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
